Suppr超能文献

新型融合咪唑并三嗪类化合物作为有前途的拓扑异构酶 II 抑制剂和促凋亡剂,对头颈部肿瘤具有更高的选择性:设计、合成与生物学评价。

Novel fused imidazotriazines acting as promising top. II inhibitors and apoptotic inducers with greater selectivity against head and neck tumors: Design, synthesis, and biological assessments.

机构信息

Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ahram Canadian University, 6th of October City, Giza, 12566, Egypt.

Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.

出版信息

Eur J Med Chem. 2023 Nov 5;259:115661. doi: 10.1016/j.ejmech.2023.115661. Epub 2023 Jul 18.

Abstract

Although the great effectiveness of doxorubicin (Dox) in the treatment of many types of tumors, it showed limited effectiveness against the head and neck squamous cell carcinoma (HNSCC) subtype which is attributed to its reported multiple drug resistance (MDR). In the current study, we considered the essential pharmacophoric features of Dox as an effective Top. II inhibitor and sought to develop a novel set of imidazo[1,2-a] [1,3,5]triazin-2-amines (2a-2p) as a suggested anticancer option that could intercalate the DNA base pairs. We evaluated the % inhibition of the newly synthesized compounds on thirteen cancer cell lines and the analysis of structure-activity relationships revealed that the human head and neck cancer cell line (HNO97) was the most sensitive to their growth inhibition effect. Then, the IC values were recorded against the most sensitive cancer cell lines (HNO97, MDA-MB-231, and HEPG2), and compared to the normal cell line OEC (human oral epithelial cells). Compounds 2f and 2g showed very strong activities against HNO97 with IC values of (4 ± 1 and 3 ± 1.5 μg/mL), respectively, compared to that of Dox (9 ± 1.6 μg/mL). Next, a quantitative determination of human DNA Top. II concentrations in the most sensitive cell line (HNO97) were recorded for the most active anticancer derivatives. Again, compound 2f showed a superior Top. II inhibition with 87.86% compared to that of Dox (86.44%), while compound 2g achieved an inhibition of 81.37% which was close to the effect of Dox. To further investigate their effects on cell cycle progression and apoptosis induction in HNO97 cells, both 2f and 2g were selected for analysis. Both candidates arrested cell cycle progression at both the S and G2-M phases, as well as increased the early and late apoptosis phase ratios. Besides, both 2f and 2g were subjected to protein expression analysis of apoptosis-related genes (p53, BAX, IL-6, and BCL2). Moreover, the antioxidant effect of 2f and 2g was evaluated by measuring GSH, MDA, and NO markers in HNO97 cells. Furthermore, molecular docking for the newly designed tricyclic derivatives against both the Top. II and DNA double helix was carried out.

摘要

虽然多柔比星(Dox)在治疗许多类型的肿瘤方面具有显著疗效,但它对头颈部鳞状细胞癌(HNSCC)亚型的疗效有限,这归因于其报道的多重耐药性(MDR)。在本研究中,我们考虑了 Dox 作为有效拓扑异构酶 II 抑制剂的基本药效团特征,并寻求开发一系列新的咪唑并[1,2-a][1,3,5]三嗪-2-胺(2a-2p)作为一种潜在的抗癌选择,可使 DNA 碱基对嵌入。我们评估了新合成化合物对 13 种癌细胞系的抑制率,结构-活性关系分析表明,人头颈癌细胞系(HNO97)对其生长抑制作用最敏感。然后,记录了这些化合物对最敏感的癌细胞系(HNO97、MDA-MB-231 和 HEPG2)的 IC 值,并与正常细胞系 OEC(人口腔上皮细胞)进行了比较。化合物 2f 和 2g 对 HNO97 的活性非常强,IC 值分别为(4±1 和 3±1.5μg/mL),而 Dox 的 IC 值为(9±1.6μg/mL)。接下来,对最敏感细胞系(HNO97)中人类 DNA 拓扑异构酶 II 浓度进行了定量测定,以评估最有效的抗癌衍生物。同样,化合物 2f 显示出比 Dox (86.44%)更高的拓扑异构酶 II 抑制作用,达到 87.86%,而化合物 2g 达到 81.37%,接近 Dox 的效果。为了进一步研究它们对 HNO97 细胞周期进程和细胞凋亡诱导的影响,选择了 2f 和 2g 进行分析。这两种候选药物都使细胞周期进程在 S 和 G2-M 期停滞,并增加了早晚期凋亡阶段的比例。此外,对 2f 和 2g 的凋亡相关基因(p53、BAX、IL-6 和 BCL2)的蛋白表达进行了分析。此外,还通过测量 HNO97 细胞中的 GSH、MDA 和 NO 标志物来评估 2f 和 2g 的抗氧化作用。此外,对新设计的三环衍生物与拓扑异构酶 II 和 DNA 双螺旋的对接进行了分子对接。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验